Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19

Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19 This Viewpoint suggests a new dosage for pembrolizumab treatment that could decrease patients’ exposure risk to COVID-19. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19

Loading next page...
 
/lp/american-medical-association/weight-based-dosing-of-pembrolizumab-every-6-weeks-in-the-time-of-6YpFVe1tmN
Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2020.2493
Publisher site
See Article on Publisher Site

Abstract

This Viewpoint suggests a new dosage for pembrolizumab treatment that could decrease patients’ exposure risk to COVID-19.

Journal

JAMA OncologyAmerican Medical Association

Published: Nov 27, 2020

References